The DOI matches its Crossref record; 276 of the 278 references it cites were found in a registry or an index.
The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
Open accessPublished version of a preprint
Abstract
Adaptive designs (ADs) allow pre-planned changes to an ongoing trial without compromising the validity of conclusions and it is essential to distinguish pre-planned from unplanned changes that may also occur. The reporting of ADs in randomised trials is inconsistent and needs improving. Incompletely reported AD randomised trials are difficult to reproduce and are hard to interpret and synthesise. This consequently hampers their ability to inform practice as well as future research and contributes to research waste. Better transparency and adequate reporting will enable the potential benefits of ADs to be realised. This extension to the Consolidated Standards Of Reporting Trials (CONSORT) 2010 statement was developed to enhance the reporting of randomised AD clinical trials. We developed an Adaptive designs CONSORT Extension (ACE) guideline through a two-stage Delphi process with input from multidisciplinary key stakeholders in clinical trials research in the public and private sectors from 21 countries, followed by a consensus meeting. Members of the CONSORT Group were involved during the development process. The paper presents the ACE checklists for AD randomised trial reports and abstracts, as well as an explanation with examples to aid the application of the guideline. The ACE checklist comprises seven new items, nine modified items, six unchanged items for which additional explanatory text clarifies further considerations for ADs, and 20 unchanged items not requiring further explanatory text. The ACE abstract checklist has one new item, one modified item, one unchanged item with additional explanatory text for ADs, and 15 unchanged items not requiring further explanatory text. The intention is to enhance transparency and improve reporting of AD randomised trials to improve the interpretability of their results and reproducibility of their methods, results and inference. We also hope indirectly to facilitate the much-needed knowledge transfer of innovative trial designs to maximise their potential benefits. In order to encourage its wide dissemination this article is freely accessible on the BMJ and Trials journal websites. “To maximise the benefit to society, you need to not just do research but do it well” Douglas G Altman
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Adapted from Steg et al. [182]](/paper-figures/7a5ba43922b94815b6414eed1fd37d47/the-adaptive-designs-consort-extension-ace-statement-a-checklist-with-figure-1.jpg)
![Fig. 2 Redrawn from Gilson et al. [260] Reused in accordance with the terms of Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/). No changes to the original figure were made](/paper-figures/c4967b9adaa2452aa490488db9787f70/the-adaptive-designs-consort-extension-ace-statement-a-checklist-with-figure-2.jpg)
![Fig. 3 Redrawn from Pallmann et al. [22] Reused in accordance with the terms of Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/). No changes to the original figure were made](/paper-figures/af5adb783a4949fe8b065e0c7ac619ff/the-adaptive-designs-consort-extension-ace-statement-a-checklist-with-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Extensions to CONSORT have been developed to tackle the methodological issues associated with reporting different types of trial designs, data, and interventions.”
From CONSORT 2025 statement: Updated guideline for reporting randomised trials (2025) · cites this paper as [33]
Experimental — accuracy not yet measuredIn the citing paper
“Extensions to CONSORT have been developed to tackle the methodological issues associated with reporting different types of trial designs, data, and interventions.”
From CONSORT 2025 statement: updated guideline for reporting randomised trials (2025) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–276 of 276
Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development
Gu, X., Chen, N., Wei, C., Liu, S., Papadimitrakopoulou, V. A., Herbst, R. S., & Lee, J. J. (2014) · Statistics in Biosciences · doi:10.1007/s12561-014-9124-2 · Cited by 37
A Bayesian adaptive design with biomarkers for targeted therapies
Eickhoff, J. C., Kim, K., Beach, J., Kolesar, J., & Gee, J. (2010) · Clinical Trials · doi:10.1177/1740774510372657 · Cited by 37
The R Package MAMS for Designing Multi-Arm Multi-Stage Clinical Trials
Jaki, T., Pallmann, P., & Magirr, D. (2019) · Journal of Statistical Software · doi:10.18637/jss.v088.i04 · Cited by 37
Self-citationExploring changes in treatment effects across design stages in adaptive trials
Friede, T., & Henderson, R. (2008) · Pharmaceutical Statistics · doi:10.1002/pst.332 · Cited by 36
A Review of Clinical Trials With an Adaptive Design and Health Economic Analysis
Flight, L., Arshad, F., Barnsley, R., Patel, K., Julious, S. A., Brennan, A., & Todd, S. (2019) · Value in Health · doi:10.1016/j.jval.2018.11.008 · Cited by 36
Self-citationGraf, A. C., Bauer, P., Glimm, E., & König, F. (2014) · Biometrical Journal · doi:10.1002/bimj.201300153 · Cited by 35
Optimal Timing for Interim Analyses in Clinical Trials
Togo, K., & Iwasaki, M. (2013) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2013.813522 · Cited by 35
Lachin, J. M. (2009) · Clinical Trials · doi:10.1177/1740774509350327 · Cited by 35
Steg, P. G., Mehta, S. R., Pollack, C. V., Bode, C., Gaudin, C., Fanouillere, K., Moryusef, A., Wiviott, S. D., & Sabatine, M. S. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.10.001 · Cited by 35
Adaptive Enrichment Designs for Stroke Clinical Trials
Rosenblum, M., & Hanley, D. F. (2017) · Stroke · doi:10.1161/strokeaha.116.015342 · Cited by 35
Blinded Sample Size Reestimation in Multiarmed Clinical Trials
Kieser, M., & Friede, T. (2000) · Drug Information Journal · doi:10.1177/009286150003400214 · Cited by 34
Clinical Trials with an Adaptive Choice of Hypotheses
Hommel, G., & Kropf, S. (2001) · Drug Information Journal · doi:10.1177/009286150103500438 · Cited by 34
Walter, S. D., Han, H., Briel, M., & Guyatt, G. H. (2017) · Statistics in Medicine · doi:10.1002/sim.7242 · Cited by 33
Design and estimation in clinical trials with subpopulation selection
Chiu, Y., König, F., Posch, M., & Jaki, T. (2018) · Statistics in Medicine · doi:10.1002/sim.7925 · Cited by 33
Self-citationSkrivanek, Z., Berry, S. M., Berry, D. A., Chien, J. Y., Geiger, M. J., Anderson, J. H., & Gaydos, B. L. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600609 · Cited by 32
Choodari‐Oskooei, B., Parmar, M., Royston, P. J., & Bowden, J. (2013) · Trials · doi:10.1186/1745-6215-14-23 · Cited by 32
Cameron, C. G., Ewara, E. M., Wilson, F. R., Varu, A., Dyrda, P., Hutton, B., & Ingham, M. (2017) · Medical Decision Making · doi:10.1177/0272989x17711933 · Cited by 32
Practical characteristics of adaptive design in phase 2 and 3 clinical trials
Sato, A., Shimura, M., & Gosho, M. (2017) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12617 · Cited by 32
Adaptive Designs for Clinical Trials: Application to Healthcare Epidemiology Research
Huskins, W. C., Fowler, V. G., & Evans, S. R. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix907 · Cited by 32
Dimairo, M., Julious, S. A., Todd, S., Nicholl, J. P., & Boote, J. D. (2015) · Trials · doi:10.1186/s13063-015-1119-x · Cited by 31
Self-citationResponse‐adaptive clinical trials: case studies in the medical literature
Grieve, A. P. (2016) · Pharmaceutical Statistics · doi:10.1002/pst.1778 · Cited by 31
Pritchett, Y., Jemiai, Y., Chang, Y., Bhan, I., Agarwal, R., Zoccali, C., Wanner, C., Lloyd‐Jones, D. M., Cannata-Andía, J. B., Thompson, B., et al. (2011) · Clinical Trials · doi:10.1177/1740774511399128 · Cited by 30
Self-citationUnblinded Adaptive Statistical Information Design Based on Clinical Endpoint or Biomarker
Wang, S.-J., Brannath, W., Brückner, M., Hung, H., & Koch, A. (2013) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2013.791639 · Cited by 30
Gilson, C., Chowdhury, S., Parmar, M., & Sydes, M. R. (2017) · Clinical Oncology · doi:10.1016/j.clon.2017.10.004 · Cited by 30
Self-citationCampbell, G. (2013) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2013.846873 · Cited by 29
Simulation study for evaluating the performance of response-adaptive randomization
Du, Y., Wang, X., & Lee, J. J. (2014) · Contemporary Clinical Trials · doi:10.1016/j.cct.2014.11.006 · Cited by 29
Avoidable waste in the production and reporting of evidence
Chen, Y., & Yang, K. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61591-9 · Cited by 29
Bayesian survival analysis in clinical trials: What methods are used in practice?
Brard, C., Teuff, G. L., Deley, M. L., & Hampson, L. V. (2016) · Clinical Trials · doi:10.1177/1740774516673362 · Cited by 29
On the Optimal Timing of Futility Interim Analyses
Xi, D., Gallo, P. P., & Ohlssen, D. I. (2017) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2017.1340906 · Cited by 29
Graf, A. C., Wassmer, G., Friede, T., Gera, R. G., & Posch, M. (2018) · Statistical Methods in Medical Research · doi:10.1177/0962280218777538 · Cited by 29
Cerqueira, F. P., Jesus, A. M. C., & Cotrim, M. D. (2020) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-019-00052-y · Cited by 29
Group Sequential Methods and Software Applications
Zhu, L., Ni, L., & Yao, B. (2011) · The American Statistician · doi:10.1198/tast.2011.10213 · Cited by 28
The role of adaptive trial designs in drug development
Curtin, F., & Heritier, S. R. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1321985 · Cited by 28 · cited 2×
“Notably, classification of ADs in the literature is inconsistent [13, 22], while the scope and complexity of trial adaptations and underpinning statistical methods continues to broaden [18, 20, 106].”
BackgroundInference for multimarker adaptive enrichment trials
Simon, R. M., & Simon, N. (2017) · Statistics in Medicine · doi:10.1002/sim.7422 · Cited by 28
Wang, S. (2010) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2010.514446 · Cited by 27
Pushpakom, S. P., Taylor, C., Kolamunnage‐Dona, R., Spowart, C., Vora, J. P., García‐Fiñana, M., Kemp, G. J., Whitehead, J., Jaki, T., Khoo, S., et al. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009566 · Cited by 27
Self-citationNew guidance to improve sample size calculations for trials: eliciting the target difference
Bell, M. L. (2018) · Trials · doi:10.1186/s13063-018-2894-y · Cited by 27
Jaki, T., & Wason, J. M. S. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0956-4 · Cited by 27
Self-citationWhat should be the role of homogeneity testing in adaptive trials?
Gallo, P. P., & Chuang‐Stein, C. (2008) · Pharmaceutical Statistics · doi:10.1002/pst.342 · Cited by 26
Heritier, S. R., Lo, S., & Morgan, C. C. (2011) · Statistics in Medicine · doi:10.1002/sim.4179 · Cited by 26
Trends in study design and the statistical methods employed in a leading general medicine journal
Gosho, M., Sato, Y., Nagashima, K., & Takahashi, S. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12605 · Cited by 26
Pushpakom, S. P., Kolamunnage‐Dona, R., Taylor, C., Foster, T., Spowart, C., García‐Fiñana, M., Kemp, G. J., Jaki, T., Khoo, S., Williamson, P. R., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz589 · Cited by 26
Self-citationUnplanned adaptations before breaking the blind
Posch, M., & Proschan, M. A. (2012) · Statistics in Medicine · doi:10.1002/sim.5361 · Cited by 25
Self-citationGuetterman, T. C., Fetters, M. D., Legocki, L. J., Mawocha, S., Barsan, W. G., Lewis, R. J., Berry, D. A., & Meurer, W. J. (2015) · Clinical Research and Regulatory Affairs · doi:10.3109/10601333.2015.1079217 · Cited by 25
Self-citationPoint estimation in adaptive enrichment designs
Kunzmann, K., Benner, L., & Kieser, M. (2017) · Statistics in Medicine · doi:10.1002/sim.7412 · Cited by 25
Stopping a trial early – and then what?
Wittes, J. T. (2012) · Clinical Trials · doi:10.1177/1740774512454600 · Cited by 24
Yang, X., Thompson, L., Chu, J., Liu, S., Lu, H. L., Zhou, J., Gomatam, S. V., Tang, R., Zhao, Y., Ge, Y., et al. (2016) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479016656027 · Cited by 24
A Fortran program for the design and analysis of sequential clinical trials
Whitehead, J., & Marek, P. M. (1985) · Computers and Biomedical Research · doi:10.1016/0010-4809(85)90043-6 · Cited by 23 · cited 6×
“Bayesian GSD with futility early stopping; frequency and timing of interim analyses; adaptation decision-making criteria; criteria for claiming treatment benefit “ We adopted a group-sequential Bayesian design [182] with three stages, of 40 patients each (in total), and two interim analyses after 40 and 80 randomised…”
InfluentialJiang, Y., Zhao, W., & Durkalski‐Mauldin, V. L. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.08.019 · Cited by 23
Guidelines for Statistical Analysis Plans
DeMets, D. L., Cook, T. D., & Buhr, K. A. (2017) · JAMA · doi:10.1001/jama.2017.18954 · Cited by 22
A Review of Available Software and Capabilities for Adaptive Designs
Tymofyeyev, Y. (2014) · Statistics for biology and health · doi:10.1007/978-1-4939-1100-4_8 · Cited by 21
Chen, Y. J., Li, C., & Lan, K. G. (2015) · Clinical Trials · doi:10.1177/1740774515594378 · Cited by 21
Coordinating Data Monitoring Committees and Adaptive Clinical Trial Designs
Herson, J. (2008) · Drug Information Journal · doi:10.1177/009286150804200401 · Cited by 20
Addressing Challenges and Opportunities of “Less Well-Understood” Adaptive Designs
He, W., Gallo, P. P., Miller, E. R., Jemiai, Y., Maca, J., Koury, K., Fan, X. F., Jiang, Q., Wang, C., & Lin, M. J. (2016) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479016663265 · Cited by 20
Self-citationMiller, E. R., Gallo, P. P., He, W., Kammerman, L. A., Koury, K. J., Maca, J., Jiang, Q., Walton, M. K., Wang, C., Woo, K., et al. (2016) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479016665434 · Cited by 20
Self-citationThe Agile Approach to Adaptive Research
Rosenberg, M. J. (2010) · Wiley eBooks · doi:10.1002/9780470599686 · Cited by 19
Nowacki, A. S., Zhao, W., & Palesch, Y. Y. (2015) · Statistical Methods in Medical Research · doi:10.1177/0962280214567142 · Cited by 18
Accurate p‐values for adaptive designs with binary endpoints
Heritier, S. R., Lloyd, C. J., & Lo, S. (2017) · Statistics in Medicine · doi:10.1002/sim.7324 · Cited by 18
Designing Multi-arm Multi-stage Clinical Studies
Jaki, T. (2014) · Springer eBooks · doi:10.1007/978-3-642-55345-5_3 · Cited by 17
Self-citationAdaptive Methods: When and How Should They be Used in Clinical Trials?
Porcher, R., Lecocq, B., Vray, M., d’Andon, A., Bassompierre, F., Béhier, J.-M., Bélorgey, C., Bénichou, J., Berdeaux, G., Bergougnoux, L., et al. (2011) · Therapies · doi:10.2515/therapie/2011044 · Cited by 17 · cited 2×
“As a result, patients may receive safe, effective treatments sooner than with fixed (non-adaptive) designs [19, 22 – 25].”
BackgroundPemberton, V. L., Evans, F., Gulin, J., Rosenberg, E., Addou, E., Burns, K. M., Gordon, D. J., Pearson, G. D., & Kaltman, J. R. (2018) · Clinical Trials · doi:10.1177/1740774518792271 · Cited by 16
Testing for qualitative interactions between stages in an adaptive study
Parker, R. A. (2009) · Statistics in Medicine · doi:10.1002/sim.3757 · Cited by 15
Wang, S., Peng, H., & Hung, H. M. J. (2018) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.02.004 · Cited by 15 · cited 3×
“Several studies, including regulatory reviews, have investigated the use of ADs in randomised trials [27, 29, 31, 33, 37, 45, 97, 107, 108, 112 – 119].”
BackgroundMethodAre We There Yet? Early Stopping in Clinical Trials
Wears, R. L. (2015) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2014.12.020 · Cited by 14
Statistical design for a confirmatory trial with a continuous predictive biomarker: A case study
Joshi, A., Zhang, J., & Fang, L. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.05.010 · Cited by 13
An alternative method to analyse the biomarker‐strategy design
Kunz, C. U., Jaki, T., & Stallard, N. (2018) · Statistics in Medicine · doi:10.1002/sim.7940 · Cited by 13
Self-citationChappell, R. J., Durkalski, V., & Joffe, S. (2017) · Clinical Trials · doi:10.1177/1740774517723590 · Cited by 12
Adaptive Designs: Results of 2016 Survey on Perception and Use
Hartford, A. H., Thomann, M. A., Chen, X., Miller, E. R., Bedding, A. W., Jorgens, S., Liu, L., Chen, L., & Morgan, C. C. (2018) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479018807715 · Cited by 10 · cited 2×
“Several studies, including regulatory reviews, have investigated the use of ADs in randomised trials [27, 29, 31, 33, 37, 45, 97, 107, 108, 112 – 119].”
BackgroundSteg, P. G., Mehta, S. R., Pollack, C. V., Bode, C., Cohen, M., French, W. J., Hoekstra, J. W., Rao, S. V., Rużyłło, W., & Ruiz-Nodar, J. M. (2013) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 7
Design issues and extensions of multi-arm multi-stage clinical trials
Bratton, D. (2015) · UCL Discovery (University College London) · Cited by 5
The Agile Approach to Adaptive Research: Optimizing Efficiency in Clinical Development
Rosenberg, M. J. (2010) · Cited by 4
The Utility of Adaptive Designs in Publicly Funded Confirmatory Trials
Dimairo, M. (2016) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York) · Cited by 4
Self-citationCerqueira, F. P., Jesus, A. M. C., & Cotrim, M. D. (2019) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479019831240 · Cited by 4
Analysis Following a Sequential Test
(1999) · Chapman & Hall/CRC machine learning & pattern recognition/Chapman & Hall/CRC machine learning & pattern recognition series · doi:10.1201/9781584888581.ch8 · Cited by 4
Regulations on Adaptive Design Clinical Trials
Rong, Y. (2014) · Pharmaceutical Regulatory Affairs Open Access · doi:10.4172/2167-7689.1000116 · Cited by 3
Power: Conditional, Unconditional, and Predictive
(2006) · Springer eBooks · doi:10.1007/978-0-387-44970-8_3 · Cited by 1
Research works printed but not linked: 4
- Detry MA, Lewis RJ, Broglio KR, et al. Standards for the design, conduct, and evaluation of adaptive randomized clinical trials. 2012. https://www.pcori.org/assets/Standards-for-the-Design-Conduct-and-Evaluation-of-Adaptive-Randomized-Clinical-Trials.pdf.
- Hack N, Brannath W. Estimation in adaptive group sequential trials; 2011.
- Vandemeulebroecke M. An investigation of two-stage tests. Stat Sin. 2006;16:933–51.
- Wagenmakers E-J, Gronau QF, Stefan A, et al. A Bayesian perspective on the proposed FDA guidelines for adaptive clinical trials. 2018. https://www.bayesianspectacles.org/a-bayesian-perspective-on-the-proposed-fda-guidelines-for-adaptive-clinical-trials/.
Cited by
Sorted by citations
CONSORT 2025 statement: updated guideline for reporting randomised trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081123 · Cited by 1,195
Self-citationCONSORT 2025 statement: updated guideline for reporting randomised trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00672-5 · Cited by 510
Self-citationHopewell, S., Chan, A., Collins, P. G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · JAMA · doi:10.1001/jama.2025.4347 · Cited by 444
Self-citationCONSORT 2025 statement: updated guideline for reporting randomized trials
Hopewell, S., Chan, A., Collins, P. G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03635-5 · Cited by 332
“Examples of extensions for trial designs include recommendations for adaptive designs 33 , cluster trials 34 , crossover trials 35 , early phase trials 36 , factorial trials 37 , non-inferiority and equivalence trials 38 , pragmatic trials 39 , multi-arm trials 40 , n-of-1 trials 41 , pilot and…”
Self-citationLuchini, C., Veronese, N., Nottegar, A., Shin, J. I., Gentile, G., Granziol, U., Soysal, P., Alexinschi, O., Smith, L., & Solmi, M. (2020) · Pharmaceutical Statistics · doi:10.1002/pst.2068 · Cited by 249
“transparency and improving the report of adaptive-design randomized trials, to increase both the interpretability of their results and reproducibility of their methods, results, and inference.(25)”
Method
Metadata
- Authors
- Dimairo, M., Pallmann, P., Wason, J., Todd, S., Jaki, T., Julious, S. A., Mander, A. P., Weir, C. J., Koenig, F., Walton, M. K., Nicholl, J. P., Coates, E., Biggs, K., Hamasaki, T., Proschan, M. A., Scott, J. A., Ando, Y., Hind, D., Altman, D. G., on behalf of the ACE Consensus Group, Dimairo, M., Hamasaki, T., Todd, S., Weir, C. J., Mander, A. P., Wason, J., Koenig, F., Julious, S. A., Hind, D., Nicholl, J., Altman, D. G., Meurer, W. J., Cates, C., Sydes, M., Jemiai, Y., Ashby, D., Yap, C., Waldron-Lynch, F., Roger, J., Marsh, J., Collignon, O., Lawrence, D. J., Bunce, C., Parke, T., Gazzard, G., Coates, E., Walton, M. K., Hopewell, S., Pallmann, P., Jaki, T., Biggs, K., Proschan, M. A., Scott, J. A., & Ando, Y.
- Affiliations
- University of Sheffield (GB)
- University of Edinburgh (GB)
- Newcastle University (GB)
- Cardiff University (GB)
- ORCID
- Venue
- Trials
- Published
- 2020-06-17
- Volume
- 21
- Issue
- 1
- Pages
- 528-528
- ISSN
- 1745-6215 (ISSN-L)
- PMC
- PMC7298968
- OpenAlex
- W3000741148
- Cited by
- 58
- References
- 278
- Citations by year
- 2026: 1 · 2025: 17 · 2024: 14 · 2023: 6 · 2022: 8 · 2021: 7 · 2020: 5
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Trials (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Lancaster EPrints (Lancaster University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- Cancer Research UK (16895)
- National Institute for Health and Care Research (DRF-2012-05-182, SRF-2015-08-001)
- Department of Health and Social Care
- University of Sheffield
- Medical Research Council (NIHR-SRF-2015-08-001, MR/L004933/1, MR/L004933/2, MR/N028171/1, MC_UU_12023/24, MR/L004933/1-R/N/P/B1)
- NIHR Academy (SRF-2015-08-001)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Social Sciences › Sociology and Political Science › Delphi Technique in Research
- Keywords
- adaptive design, CONSORT extension, reporting guidelines, randomised trials, research waste
- MeSH terms
- Delphi Technique, Humans, Periodicals as Topic, Publishing, Quality Control, Research Design, Reproducibility of Results, Randomized Controlled Trials as Topic, Guidelines as Topic, Consensus, Checklist
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review